21O Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005

作者：Alexandra Léary, K. Yonemori, C. Le Tourneau, Iwona Ługowska, Diégo Tosi, François Ghiringhelli, Özgür Özyılkan, Christian Caglevic, E.P. Yanez Ruiz, Sun Young Rha, M.G. Van Dongen, Ruth Perets, Ronnie Shapira‐Frommer, Takashi Doi, H-H. Chou, I. Cicin, Qiaofei Liu, T. Keenan, Jane Healy, C.I. Rojas · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.103521 · 被引用次数：3 · 研究领域：Cancer Immunotherapy and Biomarkers、Endometrial and Cervical Cancer Treatments、Prostate Cancer Treatment and Research

Vibostolimab (vibo) (anti-TIGIT) + pembrolizumab (pembro) has shown promising efficacy in cervical cancer. KEYVIBE-005 (NCT05007106) evaluated coformulated vibo/pembro in previously treated cervical cancer (cohort A).